Buy rating News & Analysis
2 articles
Market Mood
Vivani Medical (VANI) Price Target Lowered to $3.50 from $4
H.C. Wainwright analyst Yi Chen has lowered Vivani Medical's (VANI) price target to $3.50 from $4, citing an increase in the company's share count as a factor. Despite this reduction, the analyst maintains a Buy rating on the shares. This move follows the recent announcement of the company's 2025 results. The firm believes that NPM-139 may offer efficacy comparable to Wegovy with less frequent administration requirements, which could positively influence market perceptions.
Read More
Marvell (MRVL) Stock Receives Stifel Buy Rating with Nvidia Tie-Up
Stifel has reiterated its buy rating for Marvell (MRVL), citing the company's partnership with Nvidia. This collaboration potentially boosts Marvell's position in the semiconductor market, given Nvidia's prominent role in artificial intelligence and data centers. Analysts suggest that this partnership could enhance Marvell's revenue prospects. The reaffirmation of the buy rating reflects confidence in MRVL's growth trajectory amidst ongoing trends in AI technology.
Read More